

Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient

Faisal A. Al-Allaf^{1,2,3#}, Abdullah Alashwal^{4#}, Zainularifeen Abduljaleel^{1,2}, Mohiuddin M. Taher^{1,2}, Abdellatif Bouazzaoui^{1,2}, Hala Abalkhail⁴, Ahmad F. Al-Allaf⁵ and Mohammad Athar^{1,2#}

¹Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; ²Science and Technology Unit, Umm Al-Qura University, Makkah, Saudi Arabia; ³Molecular Diagnostics Unit, Department of Laboratory and Blood Bank, King Abdullah Medical City, Makkah, Saudi Arabia; ⁴King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; ⁵Faculty of Medicine, Alfaisal University, Riyadh, Saudi Arabia

Familial hypercholesterolemia (FH) is most commonly caused by mutations in the LDL receptor (LDLR), which is responsible for hepatic clearance of LDL from the blood circulation. We described a severely affected FH proband and their first-degree blood relatives; the proband was resistant to statin therapy and was managed on an LDL apheresis program. In order to find the causative genetic variant in this family, direct exon sequencing of the *LDLR*, *APOB* and *PCSK9* genes was performed. We identified a compound heterozygous mutation in the proband with missense p.(W577C) and frameshift p.(G676Afs*33) variants at exons 12 and 14 of the *LDLR* gene respectively. DNA sequencing of *LDLR* gene from the parents demonstrated that the missense variant was inherited from the mother and frameshift variant was inherited from the father. The frameshift variant resulted in a stop signal 33 codons downstream of the deletion, which most likely led to a truncated protein that lacks important functional domains, including the trans-membrane domain and the cytoplasmic tail domain. The missense variant is also predicted to be likely pathogenic and affect EGF-precursor homology domain of the LDLR protein. The segregation pattern of the variants was consistent with the lipid profile, suggesting a more severe FH phenotype when the variants are in the compound heterozygous state. The finding of a compound heterozygous mutation causing severe FH phenotype is important for the genotype-phenotype correlation and also enlarges the spectrum of FH-causative *LDLR* variants in the Arab population, including the Saudi population.

Key words: familial hypercholesterolemia (FH), low-density lipoprotein receptor (LDLR), compound heterozygous, missense variant, frameshift variant, sequencing, Arab, coronary artery disease (CAD), cholesterol, genetics

Received: 05 March, 2016; **revised:** 23 June, 2016; **accepted:** 04 October, 2016; **available on-line:** 23 November, 2016

[#]e-mail: fallaf@uqu.edu.sa (FAA-A); athar80@gmail.com, mabedar@uqu.edu.sa (MA)

[#]Authors contributed equally to the manuscript

Abbreviations: CAD, Coronary artery disease; CHD, Coronary heart diseases; FH, Familial hypercholesterolemia; LDLR, low-density lipoprotein receptor; APOB, apolipoprotein B; PCSK9, Pro-protein convertase subtilisin/kexin type 9; DNA, Deoxyribonucleic acid; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein-cholesterol; HDL, High-density lipoprotein; HDL-C, High-density-lipoprotein-cholesterol; TC, Total cholesterol; TG, Triglycerides; EDTA, Ethylenediaminetetraacetic acid; PCR, Polymerase chain reaction; EGF, Epidermal growth factor.

SUPPLEMENTAL MATERIAL


Appendix A

The *LDLR*, *APOB* and *PCSK9* gene primers used in both PCR amplification and capillary sequencing.


	Forward primers (5'-3')	Tm (°C)	Reverse primers (5'-3')	Tm (°C)	PCR Product size
<i>LDLR</i>					
Exon 1	tcctcctcttgagtgaggtgaag	58.6	tcctctcaacctattctggcg	57.1	298
Exon 2	cttgtgcttgcttaattcctg	53.3	caacatggcgagaccctgtc	55.1	339
Exon 3	ggtcttgaaccctgacctcac	56.2	aacctccccaggactcagatag	53.1	311
Exon 4-1	atgaggaaactgaggcaccgag	57	tgtcccttggaacacgtaaag	55.5	443
Exon 4-2	tccagtgaacagctccacc	55.8	gttggaaatccacttcggcac	55.8	341
Exon 5	gactcttctgagaaaatcaac	56.7	ggcacagagaatgggggatg	55.3	210
Exon 6	ttacaggcacaaccaccgtg	55.8	acctacagcactcatgtctcagtc	55.4	350
Exon 7	ggcgaagggtgggtagggg	56.5	gttgccatgtcaggaagcgc	55.7	236
Exon 8	gttccttgattacatctcccag	55	gagtctgtgcaaagttcagaggatg	56.1	359
Exon 9	tccatcgacgggtccccttgacc	61.2	agcctcatctcacctcggggcaa	60.8	273
Exon 10	tgactgtcccagagaatgatctg	56.9	cccactaaccagttcctgaagctc	57.2	415
Exon 11	ttcgttgacgcattggc	56.3	gggaaaccttcaggagcag	55	300
Exon 12	aggtgctttctgctaggtccctg	58.9	tcggttcattcttgcttgagtg	57.6	343
Exon 13	ggcaacccccgtgaaactctgtctg	65.4	gcaggaacgagatcatcagctattc	57.3	398
Exon 14	cttgaacctccttgaggaaactc	55.1	tgacagatgagcagagaggctc	56.7	335
Exon 15	tggtattttgccatgtgaccag	56.3	aggacgacacctggactccatc	56.6	439
Exon 16	tggaagtctccaagtgtccag	56.9	tcacatagcgggaggctgtg	55.9	262
Exon 17	gggatctctaaacaacataaaag	52.9	tgctctgatctggagggc	54.7	402
Exon 18	actcaccgtctccctctggc	55.4	aaaggaagaacccaaatcccaac	58.8	384
<i>ApoB</i>					
Exon 26	ggagcagtgaccacaagcttagcttg	62.9	agagttccagggtggctttgctgtatg	61.4	352
<i>PCSK9</i>					
Exon 1	ctgcacagtcctccccac	54.9	aggcccagaggaaacag	52.6	382
Exon 2	tacacctagggtttgctggg	53.8	cagtgtatatgcagtgccc	53.8	313
Exon 3	gctgtgtttgctgctgtcc	53.2	gcagagcaaatggattcagc	51.8	244
Exon 4	ggatgtgctctgtagttctgtg	55.3	ccaggatgggatgatggg	52.6	273
Exon 5	gttcatccatccagccacc	53.2	acctcccaggccaggtc	54.3	279
Exon 6	ctctgtgcctgtaagggagg	55.9	cccacgtgccacaagaag	52.6	373
Exon 7	tgagtctgcctctgcaacc	53.2	acagacctgactgccaag	53.8	316
Exon 8	gtgtgactggcaggagtc	55.4	cacacagacctccaagcc	55.4	307
Exon 9	ctgtggagggtcccctcactc	57.9	gccagcactgacacac	55.4	287
Exon 10	tgtgttttcaaagccattc	47.7	acttgtgaggaccaagcctc	53.8	318
Exon 11	agagagagggtctgatgggg	55.9	gctgtgcaggagagacag	55.4	320
Exon 12	agaaatgaagtgtgggtggg	51.8	ccattttaaagctcagcccc	51.8	348

Appendix B

A) Gel image showing the size and quality of PCR amplified product of *LDLR* exon 12.



B) Gel image showing the size and quality of PCR amplified product of *LDLR* exon 14.



Well 1: 50 bp DNA ladder, Well 2: Father, Well 3: Mother, Well 4: Proband, Well 5: Brother, Well 6: Sister